MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC

NCT02369198 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Malignant Pleural Mesothelioma
Non-Small Cell Lung Cancer

Interventions

DRUG: TargomiRs

Sponsor

Asbestos Diseases Research Foundation

Collaborators

[object Object]